Ablation of Intrahepatic Cholangiocarcinoma

Sweeney, Jennifer; Parikh, Nainesh; El-Haddad, Ghassan; Kis, Béla

doi:10.1055/s-0039-1696649

Cited by 25 publications

(35 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Microwave ablation (MWA) evolved as an alternative to RFA that allows for larger ablation zones and can be used in tissues in which RFA would not be successful, such as charred desiccated tissue [32,33]. The largest retrospective study consisting of 107 patients with primary or recurrent iCCA who underwent MWA found an OS at 1, 3, and 5 years of 93.5%, 39.6%, and 7.9%, respectively [34].…”

Section: Microwave Ablationmentioning

confidence: 99%

“…Irreversible electroporation (IRE) is a newer form of ablative technology that uses a high electrical voltage rather than thermal-based ablation such as RFA, MWA, and cryoablation [33]. There is a lack of data for IRE due to the small amount of unresectable primary or recurrent iCCAs that meet criteria for IRE treatment.…”

Section: Irreversible Electroporationmentioning

confidence: 99%

“…A systematic review of 9 studies including 21 patients with iCCA treated with IRE found a reduction in tumor size; however, the subtype of cholangiocarcinoma was not mentioned in the study [43]. IRE provides nonthermal technology which may be beneficial in primary or recurrent iCCA when there is proximity to sensitive structures [33].…”

Section: Irreversible Electroporationmentioning

confidence: 99%

See 2 more Smart Citations

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Renzulli

Ramai

Singh

et al. 2021

Cancers

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is a primary and aggressive cancer of the biliary tree. Combined hepatocellular cholangiocarcinoma (CHC) is a distinctive primary liver malignancy which has properties of both hepatocytic and cholangiocytic differentiation. CHC appears to have a worse prognosis compared to hepatocellular carcinoma, and similar to that of intrahepatic CCA. While significant advances have been made in understanding the pathophysiology and treatment of these two tumor types, their prognosis remains poor. Currently, liver resection is the primary treatment modality; however, only a minority of patients are eligible for surgery. However, the use of locoregional therapies proves an alternative approach to treating locally advanced disease with the aim of converting to resectability or even transplantation. Locoregional therapies such as transarterial chemoembolization (TACE), selective internal radiation therapy (SIRT), radiofrequency ablation (RFA), and photodynamic therapy (PDT) can provide patients with tumor control and increase the chances of survival. In this review, we appraise the evidence surrounding the use of locoregional therapies in treating patients with CCA and CHC.

show abstract

Section: Microwave Ablationmentioning

confidence: 99%

Section: Irreversible Electroporationmentioning

confidence: 99%

Section: Irreversible Electroporationmentioning

confidence: 99%

See 1 more Smart Citation

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Renzulli

Ramai

Singh

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…[19,20]. However, RFA has recently emerged as a minimally invasive treatment option for hepatic malignancies and as an alternative to resection, especially for patients who have small lesions and/or are unfit for surgical resection [21]. With regard to size, some authors consider RFA a useful technique to provide local control of small, localized, unresectable lesions; in patients with hepatocellular carcinomas (HCCs) 2 cm, for instance, RFA is considered an alternative to hepatic resection because of their comparable long-term efficacy [22,23].…”

Section: Discussionmentioning

confidence: 99%

Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience

Brandi

Rizzo

Dall’Olio

et al. 2020

International Journal of Hyperthermia

View full text Add to dashboard Cite

Background & aims: Very few data are available in literature about the role of radiofrequency ablation (RFA) in intrahepatic cholangiocarcinoma (ICC) and previous studies are mainly case reports and case series on a very small number of patients and nodules. In this study, we aimed to evaluate effectiveness and safety of RFA for the treatment of unresectable ICC. Methods: This is a retrospective observational cohort study comprising all consecutive patients treated with RFA for unresectable ICC at Policlinico Sant'Orsola Malpighi Hospital, Bologna, Italy. Primary endpoint was Local Tumor Progression-Free Survival (LTPFS) while Overall Survival (OS) was also assessed as secondary endpoint. Results: From January 2014 to June 2019, 29 patients with 117 nodules underwent RFA. Technique effectiveness 1 month after RFA was 92.3%; median LTPFS was 9.27 months. Univariate analysis and multivariate analysis showed that LTPFS was significantly related to tumor size 20 mm. At a median follow up of 39.9 months, median OS from the date of RFA was 27.5 months, with an OS of 89%, 45% and 11% at 1, 2 and 4 years, respectively. Number of overall lesions and the sum of their diameter at the moment of the first RFA significantly affected OS in multivariate analysis. Minor and major complication rates were 14% and 7%, respectively. Conclusion: Tumor size 20 mm was associated with lower LTPFS, representing a potential useful threshold value. A careful evaluation of tumor burden appears as a crucial element in choosing the best therapeutic strategy in unresectable ICC.

show abstract

“…These studies suggest that cryoablation provides an option for hepatic tumors, but compelling evidence for CCA remains insufficient. Further studies focusing on cryoablation of CCA may help demonstrate its role in a select group of patients where resection or other ablative therapies are not possible ( 103 ).…”

Section: Interventional Treatment For Ccamentioning

confidence: 99%

Interventional Treatment for Cholangiocarcinoma

Chen

Zhu

et al. 2021

Front. Oncol.

View full text Add to dashboard Cite

Cholangiocarcinoma (CCA) is the second most common type of primary liver malignancy. The latest classification includes intrahepatic cholangiocarcinoma and extrahepatic cholangiocarcinoma, with the latter one further categorized into perihilar and distal cholangiocarcinoma. Although surgical resection is the preferred treatment for CCA, less than half of the patients are actually eligible for radical surgical resection. Interventional treatment, such as intra-arterial therapies, ablation, and brachytherapy (iodine-125 seed implantation), has become an acceptable palliative treatment for patients with unresectable CCA. For these patients, interventional treatment is helpful for locoregional control, symptom relief, and improving quality of life. Herein, in a timely and topical manner, we will review these advances and highlight future directions of research in this article.

show abstract

Ablation of Intrahepatic Cholangiocarcinoma

Cited by 25 publications

References 56 publications

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma

Percutaneous radiofrequency ablation in intrahepatic cholangiocarcinoma: a retrospective single-center experience

Interventional Treatment for Cholangiocarcinoma

Contact Info

Product

Resources

About